ALPN

Alpine Immune Sciences, Inc. (ALPN) | Rumor.io

Alpine Immune Sciences

ALPN

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about ALPN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% 0

Apr 12

Vertex Pharmaceuticals ($VRTX) acquired Alpine Immune Sciences ($ALPN) in a $4.9B deal, with the transaction expected to close in Q2 2024.
The deal values Alpine shares at $65, representing a 67% premium to the previous day's close, and has resulted in a significant price increase for Alpine, with shares up 237.88% in 2024 and 780.98% year-over-year.
The acquisition is considered the largest deal in the sector for 2024 and a significant move for Vertex, with some analysts noting a good fit for the company's strategy.

Generated by AI

Sentiment

Of the messages about ALPN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	95.45% +16.67
Bearish	—	—	—	4.55% -16.67

Bullish· Apr 11

$ALPN's acquisition by Vertex Pharmaceuticals for $4.9B is a significant bullish indicator, with the acquiring company paying a premium for the asset.
Alpine Immune Sciences' pipeline candidates for autoimmune diseases have generated optimism, with the company's stock soaring 20.8% on positive sentiment.
The asset's potential sale talks and strategic moves have contributed to its impressive price gain, with one analyst upgrading the stock's price target from $47 to $65.

Bearish· Apr 10

$ALPN's stock price is likely to sell off due to the lack of real news behind the takeover rumors.
The significant short interest in $ALPN may lead to a painful squeeze for short sellers.
The stock's recent price action, closing on highs on high volume, suggests that the bearish sentiment may be unfounded, at least in the short term.

Generated by AI

Topics

Of the messages about ALPN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	0%	0%	0%	0%
Announcements	100%	100%	100%	100%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	0%
Technical Analysis	0%	0%	0%	0%

Analysts· Apr 11

RBC Capital downgraded Alpine Immune Sciences to Sector Perform, raising the price target to $65.
Morgan Stanley downgraded Alpine Immune Sciences to Equal-Weight, raising the price target to $65.
Wolfe Research downgraded Alpine Immune Sciences to Peer Perform.

Announcements· Apr 12

Vertex Pharmaceuticals has agreed to acquire Alpine Immune Sciences in a $4.9B deal, with the transaction expected to close in Q2 2024.
The acquisition values Alpine shares at $65 per share, representing a 67% premium over the company's close on the day before reports of the potential deal.
The deal marks a significant milestone for Alpine, which has seen its stock skyrocket 237.88% in 2024 and 780.98% year-over-year, with a market cap of $4.22B.

Generated by AI

Community

Of the messages about ALPN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	100%	33.1%
Newcomers	0%	0%	0%	66.9%

Regulars· Apr 11

RBC Capital downgraded ALPN to Sector Perform, but raised the price target to $65.
A model predicts povetacicept, ALPN's lead candidate, will be a $2 billion drug by 2030-2031.
Vertex Pharmaceuticals is acquiring ALPN for $4.9 billion, citing the potential of povetacicept in various autoimmune indications.

Newcomers· Apr 12

The acquisition of Alpine Immune Sciences (ALPN) by Vertex Pharmaceuticals (VRTX) for $4.9B is a significant deal, marking the largest in the sector this year.
The pivot of Alpine Immune Sciences (ALPN) to focus on autoimmune diseases, specifically IgA nephropathy, has shown promising results, with Vertex's acquisition suggesting a potential breakthrough in kidney treatment.
The Leerink Partners downgrade of Alpine Immune Sciences (ALPN) from Outperform to Market Perform, despite raising the price target, highlights the mixed sentiment surrounding the company's stock following the acquisition.

Generated by AI

News

Vertex to Buy Crinetics for $10 Billion in Biggest Deal Yet

2mo agoBloomberg.com

Also Discussed

Investors talking about ALPN also mention

#	Name	Attention
1	Immatics N.V.IMTX	0%0
2	ATXS - Astria Therapeutics, Inc.	——
3	Vera Therapeutics Inc.VERA	0%new
4	ALBO - Albireo Pharma, Inc.	——
5	KALV - KalVista Pharmaceuticals, Inc.	——
6	BIOS - BioPlus Acquisition Corp.	——
7	ISEE - IVERIC bio, Inc.	——
8	Palatin Technologies, Inc.PTN	0%0
9	Tilly's Inc.TLYS	0%new
10	SINO - Singularity Future Technology Ltd.	——